There were two novel small molecules approved in April 2022:
- mavacamten (Camzyos), an oral cardiac myosin inhibitor
- oteseconazole (Vivjoy), an oral antifungal (jump to section)
This deep dive explores each drug in more detail, including the industry context, the clinical data, the target rationale, mechanisms of action, and drug origins.
See our overview of all 36 of the novel small molecule and large molecule FDA approvals for 2022 here.
request a trial
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
